Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates

Despite the rapid creation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines, the precise correlates of immunity against severe Coronavirus Disease 2019 (COVID-19) are still unknown. Neutralizing antibodies represent a robust surrogate of protection in early Phase III studies,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Daniel Y., Gorman, Matthew J., Yuan, Dansu, Yu, Jingyou, Mercado, Noe B., McMahan, Katherine, Borducchi, Erica N., Lifton, Michelle, Liu, Jinyan, Nampanya, Felix, Patel, Shivani, Peter, Lauren, Tostanoski, Lisa H., Pessaint, Laurent, Van Ry, Alex, Finneyfrock, Brad, Velasco, Jason, Teow, Elyse, Brown, Renita, Cook, Anthony, Andersen, Hanne, Lewis, Mark G., Lauffenburger, Douglas A., Barouch, Dan H., Alter, Galit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071142/
https://www.ncbi.nlm.nih.gov/pubmed/35512013
http://dx.doi.org/10.1371/journal.pbio.3001609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071142/
https://www.ncbi.nlm.nih.gov/pubmed/35512013
http://dx.doi.org/10.1371/journal.pbio.3001609

Ejemplares similares